Clinical Trial Detail

NCT ID NCT04086264
Title IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

acute myeloid leukemia

Therapies

IMGN632

IMGN632 + Venetoclax

Azacitidine + IMGN632

Azacitidine + IMGN632 + Venetoclax

Age Groups: senior adult

No variant requirements are available.